Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 1, 2009, Pages 57-62

  Bayan, Kadim ^a   Tüzün, Yekta ^a   Yilmaz, Şerif ^a   Canoruc, Naime ^a   Dursun, Mehmet ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Idiopathic portal hypertension; Thrombophilic mutations

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; AMINOTRANSFERASE; ANTITHROMBIN III; APOLIPOPROTEIN B; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BILIRUBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; GLYCOPROTEIN IIIA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; HYBRIDIZATION; IDIOPATHIC DISEASE; IDIOPATHIC PORTAL HYPERTENSION; INHERITANCE; MALE; PATHOGENESIS; PORTAL HYPERTENSION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD; THROMBOPHILIA;

ADULT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS B; FACTOR V; FACTOR XIII; FEMALE; FIBRINOGEN; GENETIC DISEASES, INBORN; HUMANS; HYPERTENSION, PORTAL; INTEGRIN BETA3; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION, MISSENSE; PEPTIDYL-DIPEPTIDASE A; PROTHROMBIN;

EID: 67449085330     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0244-8     Document Type: Article

References (51)

1. Boyer JL, Sen Gupta KP, Biswas SK et al (1967) Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med 66:41-68
2. Sama SK, Bhargava S, Nath NG et al (1971) Non-cirrhotic portal fibrosis. Am J Med 51:160-171
3. Levison DA, Kingham JG, Dawson AM et al (1982) Slow cirrhosis or no cirrhosis? A lesion causing benign intrahepatic portal hypertension. J Hepatol 137:253-272
4. Wanless IE (1990) Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11:787-797
5. Mikkelsen WP, Edmondson HA, Peters RL et al (1965) Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis). Ann Surg 162:602-608
6. Sciot R, Staessen D, Van Damme B et al (1988) Incomplete septal cirrhosis: Histopathological aspects. Histopathology 13:593-603
7. Halllenbeck GA, Adson MA (1961) Esophagogastric varices without hepatic cirrhosis. A clinical study of treatment of their bleeding in 72 cases. Arch Surg 83:370-383
8. Polish E, Christie J, Cohen A et al (1962) Idiopathic presinusoidal portal hypertension (Banti's syndrome). Ann Intern Med 56:624-627
9. Basu AK, Boyer J, Bhattacharya R et al (1967) Non-cirrhotic portal fibrosis with portal hypertension: A new syndrome. I. Clinical and function studies and result of operations. II. Histopathological studies. Ind J Med Res 55:336-339
10. Bernard PH, Le Bail B, Cransac M et al (1995) Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. J Hepatol 22:495-499
11. Sarin SK (1989) Non-cirrhotic portal fibrosis. Gut 5:336-351
12. Kohno K, Ohnishi K, Omata M (1988) Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 94:787-796
13. Huet PM, Guillaume E, Cote J et al (1975) Noncirrhotic presinusoidal portal hypertension associated with chronic arsenical intoxication. Gastroenterology 68:1270-1277
14. Yamaguchi E, Yamanoi A, Ono T et al (2007) Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. J Gastroenterol Hepatol 22(7):1134-1140
15. Guha Mazumdar DN, Gupta JD, Dasgupta JD (1991) Arsenic and non-cirrhotic portal hypertension. J Hepatol 13:376
16. Vakili C, Farahvash MJ, Bynum TE (1992) 'Endemic' idiopathic portal hypertension. Report on 32 patients with noncirrhotic portal fibrosis. World J Surg 16:118-125
17. Rai T, Ohira H, Fukaya E et al (2004) A case of merged idiopathic portal hypertension in course of mixed connective tissue disease. Hepatol Res 30:51-55
18. Takagi K, Nishio S, Akimoto K et al (2006) A case of systemic sclerosis complicated by idiopathic portal hypertension: Case report and literature review. Mod Rheumatol 16:183-187
19. Saito K, Nakanuma Y, Takegoshi K et al (1993) Nonspecific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology 40:163-166
20. Girard M, Amiel J, Fabre M et al (2005) Adams-Oliver syndrome and hepatoportal sclerosis: Occasional association or common mechanism? Am J Med Genet A 135:186-189
21. Sarin SK, Malhotra V, Mehra NK et al (1987) Familial aggregation in non-cirrhotic portal fibrosis: A study of four families. Am J Gastroenterol 82:1130-1134
22. Aikat BK, Bhusnurmath SR, Chhuttani PN et al (1979) The pathology of noncirrhotic portal fibrosis. Hum Pathol 10:405-418
23. Okuda K, Nakashima T, Okudaira M et al (1982) Liver pathology of idiopathic portal hypertension. Comparison with non-cirrhotic portal fibrosis of India. Liver 2:176-192
24. Nakanuma Y, Tsuneyama K, Ohbu M et al (2001) Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 197:65-76
25. Ohbu M, Okudaira M, Watanabe K et al (1994) Histopathological study of intrahepatic aberrant vessels in cases of non-cirrhotic portal hypertension. Hepatology 20:302-308
26. Sarin SK, Kapoor D (2002) Non-cirrhotic portal fibrosis: Current concepts and management. J Gastroenterol Hepatol 17(5):526-534
27. Hillaire S, Bonte E, Denninger MH et al (2002) Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: A re-evaluation in 28 patients. Gut 51(2):275-280
28. Okuda K (1986) Idiopathic portal hypertension. In: Thomas HC, Jones EA (eds) Recent advances in hepatology, 2nd edn. Edinburgh, Churchill Livingstone, pp 93-108
29. Dhiman RK, Chawla Y, Vasishta RK et al (2002) Non-cirrhotic portal fibrosis (idiopathic portal hypertension): Experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 17(1):1-5
30. Okuda K, Kono K, Ohnishi K et al (1984) Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology 86:600-610
31. Ramalingaswami V, Wig KL, Sama SK (1962) Cirrhosis of the liver in northern India. A clinicopathological study. Arch Intern Med 110:350-358
32. Sarin SK, Sachdev G, Nanda R (1986) Follow-up of patients after variceal eradication. A comparison of patients with cirrhosis, non-cirrhotic portal fibrosis and extrahepatic obstruction. Ann Surg 202:78-82
33. Harmanci O, Bayraktar Y (2007) Clinical characteristics of idiopathic portal hypertension. World J Gastroenterol 13(13):1906-1911
34. Okuda K (1988) Idiopathic portal hypertension and protein C deficiency. Hepatology 8(5):1110-1111
35. Ishii M, Katada Y (2003) Idiopathic portal hypertension in a systemic sclerosis patient heterozygous for factor V Leiden mutation. Rheumatol Int 23(1):44-46
36. Bertina RM, Koeleman BPC, Koster T et al (1994) Mutation in blood coagulation factor associated with resistance to activated protein C. Nature 369:64-67
37. Dönmez Y, Kanadasi M, Tanriverdi K et al (2004) Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 45(3):505-512
38. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593-1596
39. Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700-4702
40. Mikkola H, Syrjälä M, Rasi V et al (1994) Deficiency in the A-subunit of coagulation factor XIII: Two novel point mutations demonstrate different effects on transcript levels. Blood 84(2):517-525
41. Dong QL, Zhang C (2004) Association between the polymorphism of beta-fibrinogen gene-455G/A and ischemic stroke. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21(3):274-276
42. Humphries S, Henry J, Montgomery H (1999) Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrin 10:S17-S21
43. Tàssies D, Espinosa G, Muñoz-Rodríguez FJ et al (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43:2349-2358
44. Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79:975-979
45. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: Impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081-1086
46. Seguí R, Estellés A, Mira Y et al (2000) PAI-1 promoter 4G/ 5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122-128
47. Beer JH, Pederiva S, Pontiggia L (2000) Genetics of platelet receptor single-nucleotide polymorphisms: Clinical implications in thrombosis. Ann Med 32(Suppl 1):10-14
48. Slowik A, Dziedzic T, Turaj W et al (2004) A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke 35(7):1589-1593
49. den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-62
50. van der Put NM, Gabreëls F, Stevens EM, Smeitink JA et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neuraltube defects? Am J Hum Genet 62:1044-1051
51. Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172